… on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program features and updates: ProQR to … Axiomer®: ProQR will introduce its novel, proprietary RNAediting platform technology. Art Levin, Ph.D., an …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … excited by the potential of our next-generation Axiomer RNAediting technology. In addition to using this platform to …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … Annual Conference A presentation titled “Therapeutic RNAediting by Axiomer ® editing oligonucleotides” by Janne …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced that it has …
… two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets … collaboration are not disclosed. ProQR is developing its RNA platform technology in areas of ophthalmology, cystic … look forward to collaborating with ProQR and its exciting RNAediting technologies.” About ProQR ProQR Therapeutics is …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced the pricing …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the …